(MedPage Today) — MADRID — The novel oral cardiac myosin inhibitor aficamten improved exercise capacity and symptoms of obstructive hypertrophic cardiomyopathy (HCM) better than standard beta-blocker treatment, the MAPLE-HCM randomized trial…
Source link : https://www.medpagetoday.com/meetingcoverage/esc/117221
Author :
Publish date : 2025-08-30 07:18:00
Copyright for syndicated content belongs to the linked Source.
